NYSE:BHVN Biohaven (BHVN) Stock Price, News & Analysis $9.44 -0.01 (-0.05%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$9.38 -0.06 (-0.69%) As of 05/22/2026 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biohaven Stock (NYSE:BHVN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Biohaven alerts:Sign Up Key Stats Today's Range$9.43▼$9.9250-Day Range$8.10▼$11.0052-Week Range$7.48▼$18.57Volume1.44 million shsAverage Volume1.94 million shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice Target$22.27Consensus RatingModerate Buy Company Overview Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships. The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine. Its lead product, rimegepant—commercially marketed under the name NURTEC® ODT—has been approved for both acute migraine relief and migraine prevention in adults. Biohaven’s pipeline also includes atogepant, a once-daily oral CGRP receptor antagonist in late-stage development for migraine prevention, as well as earlier-stage candidates targeting N-methyl-D-aspartate (NMDA) receptors for chronic pain and other neurological disorders. In addition to its internal programs, Biohaven has established global licensing agreements and co-development partnerships to expand the reach of its migraine therapies in key markets such as Europe, Canada and Asia. The company leverages a hybrid model of in-house development and external collaborations to accelerate clinical progress and broaden patient access. Under the leadership of Founder and Chief Executive Officer Dr. Vlad Coric, Biohaven has built a multidisciplinary management team with deep experience in neuroscience drug development and commercial operations. Together, they aim to advance the company’s portfolio through late-stage clinical trials and regulatory submissions, with the goal of delivering novel treatments that improve patient outcomes in neurological and central nervous system disorders.AI Generated. May Contain Errors. Read More Biohaven Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreBHVN MarketRank™: Biohaven scored higher than 52% of companies evaluated by MarketBeat, and ranked 478th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBiohaven has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 2 strong buy ratings, 9 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialBiohaven has a consensus price target of $22.27, representing about 135.8% upside from its current price of $9.45.Amount of Analyst CoverageBiohaven has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biohaven's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($3.00) to ($2.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 10.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biohaven's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.16% of the float of Biohaven has been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 14.37, which indicates bearish sentiment.Change versus previous monthShort interest in Biohaven has recently increased by 4.56%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. News and Social Media2.2 / 5News SentimentN/A News SentimentBiohaven has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Biohaven this week, compared to 8 articles on an average week.Search InterestOnly 6 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have not sold or bought any company stock.Percentage Held by Insiders13.80% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biohaven's insider trading history. Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BHVN Stock News HeadlinesBank of America Securities Reaffirms Their Hold Rating on Biohaven Ltd. (BHVN)May 24 at 9:43 AM | theglobeandmail.comBiohaven Ltd. (BHVN) Receives a Hold from BernsteinMay 15, 2026 | theglobeandmail.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Biohaven Shareholders Back Board, Auditor and Executive PayMay 8, 2026 | theglobeandmail.comBiohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf Registration - What's ChangedMay 7, 2026 | finance.yahoo.comBiohaven Expands At-The-Market Equity Offering ProgramMay 5, 2026 | tipranks.comA Look At Biohaven (BHVN) Valuation After Narrower Q1 Loss And New Pivotal Trial And Funding PlansMay 5, 2026 | finance.yahoo.comBiohaven Reports Recent Business Developments and First Quarter 2026 Financial ResultsMay 4, 2026 | prnewswire.comSee More Headlines BHVN Stock Analysis - Frequently Asked Questions How have BHVN shares performed this year? Biohaven's stock was trading at $11.26 at the start of the year. Since then, BHVN shares have decreased by 16.1% and is now trading at $9.4450. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) released its quarterly earnings results on Monday, May, 4th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.02. When did Biohaven IPO? Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers. Who are Biohaven's major shareholders? Biohaven's top institutional shareholders include Janus Henderson Group PLC (11.65%), Stempoint Capital LP (1.06%), ARS Investment Partners LLC (0.92%) and Simplify Asset Management Inc. (0.60%). Insiders that own company stock include John W Childs, Gregory Bailey, Vlad Coric, Matthew Buten, George C Clark and Irina Antonijevic. View institutional ownership trends. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings5/04/2026Today5/25/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 5 days ago, BHVN's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CIK1935979 Webwww.biohavenpharma.com Phone203-404-0410FaxN/AEmployees239Year Founded2014Price Target and Rating Average Price Target for Biohaven$22.27 High Price Target$75.00 Low Price Target$9.00 Potential Upside/Downside+135.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($5.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$738.82 million Net MarginsN/A Pretax MarginN/A Return on Equity-866.46% Return on Assets-137.99% Debt Debt-to-Equity Ratio1.87 Current Ratio7.41 Quick Ratio7.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book10.98Miscellaneous Outstanding Shares150,560,000Free Float129,784,000Market Cap$1.42 billion OptionableOptionable Beta1.32 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:BHVN) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredGold surged 600 dollars last time this indicator peakedThe Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
